ONTARIO, Calif., March 8, 2004 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, announced today that Linda H. Masterson, President and Chief Executive Officer, will present an overview of LifePoint's business at the BioSquare 2004 Conference at the Convention Center in Basel Switzerland on Thursday March 11.
BioSquare 2004 is a unique platform for the top management of biotechnology and medical device companies to meet with institutional investors and key senior executives from companies in the pharmaceutical, medical device, agricultural, food and finance industries. At the conference in 2003, 144 companies made presentations to participants from over 500 companies. Additionally, over 2,750 one-on-one partnering meetings were held. BioSquare is considered to be one of the premiere partnering events in the industry.
"Calendar year 2004 has been an eventful year thus far for LifePoint," stated Linda H. Masterson, President and CEO of LifePoint, Inc. "LifePoint started shipping product in February 2004, with an initial focus on current customers that have been using the LifePoint(r) IMPACT(r) Test System. Our focus for the remainder of calendar year 2004 is to focus on sales and production scale-up. We welcome the opportunity to talk about LifePoint and our products to the European community, where we believe there is considerable market receptivity to our product."
About LifePoint, Inc.
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT Test System -- a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future, ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets -- law enforcement, industrial workplace and medical emergency room -- are estimated to be over $1.6 billion in total opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to the need to hire personnel, dependence on third parties for certain marketing efforts, FDA 510(k) clearance in medical markets, market acceptance and potential need for additional financing. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
LifePoint(r) and IMPACT(r) are trademarks of LifePoint, Inc.